AzTrials
AzTrials

Plasmodium InfectionNCT05117567

Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Lao PDR and Cambodia

A study testing Personal protection package in people with Plasmodium Infection, run by Macfarlane Burnet Institute for Medical Research and Public Health Ltd.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This stepped-wedge cluster-randomized controlled trial with nested mixed methods study will assess the effectiveness, acceptability, feasibility and cost-effectiveness of a personal protection package to reduce malaria transmission among mobile and migrant populations (MMPs) and the general population in their… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Plasmodium Infection
What is being tested?
Personal protection package
Could I receive a placebo?
No, everyone receives an active treatment
How many people
5,868 participants
Where
No sites listed yet
Study dates
1 Dec 2021to Jun 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Mobile and migrant individuals aged 18 years and over in selected villages including:
  • Traditional slash-and-burn and paddy field farming communities visiting their forest farms (commonly ethnic minority groups)
  • Seasonal agricultural laborers
  • Forest workers in the informal sector (hunters, small-scale gem/gold miners, people gathering forest products (precious timber, construction timber, rattan/bamboo)
  • Transient or mobile camp residents associated with commercial projects (road/pipeline construction, large-scale logging, deep seaport projects, etc.)
  • Formal and informal cross-border migrant workers
Show all 10Show fewer
  • For qualitative research component, local health stakeholders meeting the following criteria will be eligible:
  • Aged 18 years and over
  • The local health stakeholders such as health centre staff, Operational District Malaria Supervisor (ODMS), and Provincial Malaria Supervisor (PMS), and basic health staff such as malaria unit staff in health centres, midwives, health assistants, district health officers and district focal person from CMPE and CNM
  • Health staff members from HPA and Lao malaria community service organisations

Who cannot join

  • A village will be excluded from the study if:
  • The village has an VHV/VMW program operated by any organizations other than CMPE, CNM, HPA, malaria CSOs in Lao PDR The village has no malaria cases or API less than 1 in any of the past three years (2018 - 2020) The village has no MMPs The village has no VHV/VMW The village has a government health facility for provision of malaria services

Trial locations and contacts

No sites are listed yet.

Freya JI Fowkes, DPhil contact

+613 8506 2310

freya.fowkes@burnet.edu.au

Julia C Cutts, PhD contact

+61408397376

julia.cutts@burnet.edu.au

About this study

Official title: A Personal Protection Package for Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Lao PDR and Cambodia: A Stepped-wedge Trial With Nested Mixed-methods Study

This stepped-wedge cluster-randomized controlled trial with nested mixed methods study will assess the effectiveness, acceptability, feasibility and cost-effectiveness of a personal protection package to reduce malaria transmission among mobile and migrant populations (MMPs) and the general population in their residing villages in Lao People's Democratic Republic (PDR) and Cambodia.

Read the detailed description

Over the last decade, the burden of malaria has fallen dramatically in the Greater Mekong Subregion, with deaths falling by 95% and cases by 76% between 2012 and 2019.The declining malaria burden in GMS has largely attributed by the deployment of interventions of malaria prevention tools such as long-lasting Insecticidal Nets (LLIN), and widespread availability of rapid diagnostic tests and artemisinin combination therapies. However, residual transmission still exists among high risk populations, particularly mobile and migrant populations who enter forests for work. New interventions targetting these high risk groups are needed if countries of the Greater Mekong Subregion are to achieve malaria elimination by 2030. The study will be conducted in malaria endemic areas of Lao PDR (Attapeu, Saravanh, Savannakhet and Khammouane Provinces) and Cambodia (Preah Vihear, Stung Treng and Ratanakiri Provinces) which have large forest going MMP populations. The aim of the study is to assess the effectiveness, acceptability, feasibility and cost-effectiveness of a personal protection package to reduce malaria transmission among mobile and migrant populations (MMPs) and the general population in their residing villages in Lao People's Democratic Republic (PDR) and Cambodia. The personal protection package comprises a long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and a behavioural change communication (BCC) package tailored to mobile and migrant populations. The study design is a stepped-wedge cluster-randomized controlled trial with nested mixed methods study. The stepped-wedge cluster randomized trial will estimate the effectiveness of a personal protection package provided to forest-going MMPs (the intervention) delivered by village malaria volunteers at the site (village/worksite) level on reducing Plasmodium spp. infections. Whilst the personal protection package will be provided to mobile and migrant populations in each village in a step-wise manner, primary and secondary outcomes relating to malaria testing will be collected in all consenting individuals in the village who present for malaria rapid diagnostic tests, whether they are mobile and migrant people or not.

The open stepped-wedge cluster-randomised controlled trial, randomized at the volunteer level (i.e. the volunteer and the village / workplaces they service), will be implemented between July 2021 to June 2022. The personal protection package for MMPs will be implemented sequentially in a minimum of ~488 villages serviced by approximately ~488 VMWs (~428 in Lao PDR and ~60 in Cambodia). Villages from each country will be randomised into 11 ordered blocks, with blocks transitioned from control (no personal protection package) to intervention (distribution of personal protection package) states at monthly intervals (10 blocks of 44 villages for the first 10 steps and a block of 48 villages transitioned at the last step). This follows an initial baseline control period of one-month at the start of the study

Approximately 11 RDTs per month will be undertaken in each study site (village/ worksite). Given the design we estimate that the study has power to detect a relative minimum detectable difference of 34% (OR = 0.66) in odds of RDT-detectable malaria infection due to the intervention (assuming a village intraclass correlation [ICC]= 0.42; 5% significance; 90% power and 1% RDT malaria prevalence).

For the stepped-wedged cluster randomized trial, both descriptive and primary outcome trial analyses will be performed. Using Stata version 15, differences in prevalence of Plasmodium spp. infections will be estimated across intervention and control periods using generalized linear mixed modelling (e.g. logit link function and binomial distribution) with crossed random effects for village and time, and intervention state, time and seasonality estimated as independent fixed factors. Temporal and spatial trends of Plasmodium spp. infections will also be explored including analysis of the effectiveness of the intervention across the study period. We will also explore any village-specific heterogeneity in effect by specifying a random effect for the intervention. Generalised linear mixed modelling will be extended to include model terms for country (main and interaction effects), and these will used to assess the extent of country-specific heterogeneity in intervention effect. The same approach will be used to assess risk group-specific heterogeneity (MMP, forest-goer, villager) in intervention effect.

Being tested
Personal protection package
Keywords
malaria, prevention, vector, migrant, elimination, vivax, falciparum, community-delivered, intervention
Medical subject headings
Malaria

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Personal protection packageCombination product

    A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and MMP-tailored behavioural change communication (BCC) package

Study groups in NCT05117567
Study groupRoleWhat they receive
Personal protection packageExperimentalA personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and mobile and migrant population-tailored behavioural change communication (BCC) package
Receives: Combination Product: Personal protection package
ControlNo interventionNo personal protection package

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Plasmodium spp. infection diagnosed by RDT

    Change in the number of Plasmodium spp. infections detected by RDT per week per village

    Measured: Assessed weekly, longitudinally over 12 months

Secondary outcomes (10)
  1. Symptomatic malaria diagnosed by RDT

    Change in the number of symptomatic Plasmodium spp. infections detected by RDT per week per village

    Measured: Assessed weekly, longitudinally over 12 months

  2. Plasmodium spp. infection as determined by polymerase chain reaction (PCR) on RDT cassette samples

    Change in the prevalence of Plasmodium spp. infection as determined by polymerase chain reaction (PCR) from RDT cassette samples

    Measured: Assessed weekly, longitudinally over 12 months

  3. Plasmodium spp. infection as determined by polymerase chain reaction (PCR) on dried blood spot samples

    Change in the prevalence of Plasmodium spp. infection as determined by polymerase chain reaction (PCR) from dried blood spot (DBS) samples

    Measured: Assessed weekly, longitudinally over 12 months

  4. Plasmodium spp. infections with drug resistance mutations

    Change in the prevalence of Plasmodium spp. infection with drug resistance mutations.

    Measured: Assessed weekly, longitudinally over 12 months

  5. Prevalence of antibodies to Plasmodium spp.

    Prevalence of antibodies to Plasmodium spp. determined by Enzyme Linked Immunosorbent assay (ELISA) from RDT and DBS samples

    Measured: Assessed weekly, longitudinally over 12 months

  6. Levels of antibodies to Plasmodium spp.

    Levels of antibodies to Plasmodium spp. determined by Enzyme Linked Immunosorbent assay (ELISA) from RDT and DBS samples

    Measured: Assessed weekly, longitudinally over 12 months

  7. Prevalence of antibodies to vector salivary antigens

    Levels of antibody biomarkers of vector exposure

    Measured: Assessed weekly, longitudinally over 12 months

  8. Levels of antibodies to vector salivary antigens

    Levels of antibody biomarkers of vector exposure

    Measured: Assessed weekly, longitudinally over 12 months

  9. Levels of knowledge, attitude and practice regarding malaria prevention among MMPs

    Focus group discussions

    Measured: At approximately 12 months

  10. Proportion of survey respondents (MMPs) who accept and are willing to use/ did use the personal protection package according to the protocol

    Questionnaire

    Measured: At approximately 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Nov 2021
  2. Study start1 Dec 2021 (estimated)
  3. Primary completionJun 2022 (estimated)
  4. Study completionJun 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Model description
Stepped-wedge cluster-randomized controlled trial (one-way crossover) with nested mixed methods study
Masking
None (open label)
Enrolment
5,868 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05117567
Sponsor's protocol ID
388/21_forest_Cambodia_Laos
Status last verified
Nov 2021
First submitted
16 Aug 2021
Last updated
11 Nov 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Gabaldon Figueira JC, Wagah MG, Adipo LB, Wanjiku C, Maia MF. Topical repellents for malaria prevention. Cochrane Database Syst Rev. 2023 Aug 21;8(8):CD015422. doi: 10.1002/14651858.CD015422.pub2.

    PubMed 37602418
  • Htike W, Oo WH, Lynn T, Sovanda L, Agius PA, Oo MC, Galau NH, Thu KM, Zaw AK, Htwe EP, Cutts JC, Kearney EA, Scott N, O'Flaherty K, Wang B, Khamlome B, Vilay P, Siv S, Fowkes FJI. Reducing malaria transmission in forest-going mobile and migrant populations in Lao PDR and Cambodia: protocol for stepped-wedge cluster-randomised controlled trial. BMC Infect Dis. 2022 Sep 24;22(1):747. doi: 10.1186/s12879-022-07724-5.

    PubMed 36153501

Questions about this trial

What is this clinical trial studying?

A study testing Personal protection package in people with Plasmodium Infection, run by Macfarlane Burnet Institute for Medical Research and Public Health Ltd.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 11 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Freya JI Fowkes, DPhil (+613 8506 2310, freya.fowkes@burnet.edu.au), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Plasmodium spp. infection diagnosed by RDT (time frame: Assessed weekly, longitudinally over 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05117567, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Nov 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in